Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-positive adults with persistently normal ALT
2007-005698-76Phase 4Terminated
- Sponsor
- Luigi Sacco University Hospital
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection, sponsored by Luigi Sacco University Hospital. Primary endpoints: Efficacy, Tolerability and 4 more. Started Oct 2007; status: terminated.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-005698-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005698-76.